International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064

Downloads: 122 | Views: 200

Research Paper | Medical Surgical | India | Volume 8 Issue 8, August 2019

A Comparative Study to Evaluate Efficacy and Safety of Eye Drop Travoprost 0.004% with Tafluprost 0.0015% in Patient with Primary Open Angle Glaucoma

Dr Atula Yadav | Dr Ashok Kumar Bairwa | Dr Pooja Sharma

Abstract: BACKGROUND Glaucoma is a leading cause of blindness worldwide. Elevated intraocular pressure (IOP) is considered a key risk factor for the progression of glaucoma. Prostaglandin analogs are among the most potent IOP lowering therapies currently available. Aims and Objective: This is a comparative and prospective study to evaluate the IOP lowering efficacy and safety of travoprost (TRAV) 0.004 % compared with tafluprost (TAF) 0.0015 % in patients with primary open-angle glaucoma (POAG) over 8 weeks. MATERIALS AND METHODS This prospective, randomized, comparative was conducted on 50 patients of POAG, The patients were assigned to one of the two treatment groups, either TRAV or TAF monotherapy administered as 1 drop daily at 8 pm. Intraocular pressure (IOP) was measured at each visit (1 week, 4 weeks, 8 weeks), slit-lamp bio-microscopy was done and side effects noted at each visit. RESULTS The mean IOP reduction in TRAV group from 28.04±3.05 to 19.28±1.59 thus resulting in fall of 8.76 ± 2.22 mm Hg (30.89 %) and in TAF group it decreased from 27.52±2.74 to 19.64±1.44 resulting in fall of 7.88 ± 2.52 mm Hg (28.18 %). These data suggest that both groups provides modest IOP control but this was statistically not significant. ( p=0.197). In both treatment groups, the most frequently reported adverse event at 8 weeks was conjunctival hyperaemia observed in 7 (28 %) patients of group A (TRAV) and 8 (32 %) patients of group B (TAF), though the difference was not statistically significant. CONCLUSION Both Travoprost 0.004 % and Tafluprost 0.0015 % in patients with primary open angle glaucoma demonstrated good IOP control. Travoprost has a few advantages over Tafluprost including its potency & efficacy but these are not statistically significant, both exhibit almost similar safety profile.

Keywords: Conjunctival hyperaemia, Intraocular pressure, Primary open-angle glaucoma POAG, Prostaglandin analogs, Tafluprost, Travoprost

Edition: Volume 8 Issue 8, August 2019,

Pages: 1864 - 1870

How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link

Verification Code will appear in 2 Seconds ... Wait